Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses

Ipilimumab is effective for patients with melanoma, but not for those with less immunogenic tumors. We report a phase II trial of ipilimumab with concurrent or sequential stereotactic ablative radiation therapy to metastatic lesions in the liver or lung (). Ipilimumab (every 3 weeks for 4 doses) was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Welsh, James W., Tang, Chad, de Groot, Patricia, Naing, Aung, Hess, Kenneth R., Heymach, John V., Papadimitrakopoulou, Vassiliki A., Cushman, Taylor R., Subbiah, Vivek, Chang, Joe Y., Simon, George R., Ramapriyan, Rishab, Barsoumian, Hampartsoum B., Menon, Hari, Cortez, Maria A., Massarelli, Erminia, Nguyen, Quynh, Sharma, Padmanee, Allison, James P., Diab, Adi, Verma, Vivek, Raju, Uma, Shaaban, Sherif G., Dadu, Ramona, Cabanillas, Maria E., Wang, Kelvin, Anderson, Clark, Gomez, Daniel R., Hahn, Stephen, Komaki, Ritsuko, Hong, David S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891218/
https://ncbi.nlm.nih.gov/pubmed/31658994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados